Having hard time believing, as a kidney doctor, that the data from Ozempic will have such an impact on CKD patients to the level dialysis stocks have reacted. While I believe it will delay CKD progression, a la gliflozin family, I doubt it will be curative. $DVA$NVO$LLY ...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.